
Sign up to save your podcasts
Or


Eli Lilly Chief Executive Officer Dave Ricks talks about paying $2.5 billion for a cancer drug being developed by Scorpion Therapeutics. He also says Lilly's experimental weight-loss pill could be approved in early 2026. He speaks to Bloomberg's Katie Greifeld from the JPMorgan Healthcare Conference in San Francisco.
See omnystudio.com/listener for privacy information.
By Bloomberg4.6
1616 ratings
Eli Lilly Chief Executive Officer Dave Ricks talks about paying $2.5 billion for a cancer drug being developed by Scorpion Therapeutics. He also says Lilly's experimental weight-loss pill could be approved in early 2026. He speaks to Bloomberg's Katie Greifeld from the JPMorgan Healthcare Conference in San Francisco.
See omnystudio.com/listener for privacy information.

956 Listeners

404 Listeners

1,176 Listeners

2,171 Listeners

1,952 Listeners

420 Listeners

969 Listeners

791 Listeners

195 Listeners

62 Listeners

211 Listeners

1,302 Listeners

60 Listeners

30 Listeners

66 Listeners

455 Listeners

4 Listeners

58 Listeners

233 Listeners

229 Listeners

62 Listeners

83 Listeners

79 Listeners

74 Listeners

86 Listeners

400 Listeners

12 Listeners

7 Listeners

2 Listeners

72 Listeners